Xeris Biopharma Holdings Stock Price, News & Analysis

Xeris Biopharma (Nasdaq: XERS), a growth-oriented biopharmaceutical company, has scheduled the release of its first quarter 2025 financial results for Thursday, May 8, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day to discuss their financial and operational performance.

Interested participants can pre-register for the call through the provided link. A replay of the conference call will be available until May 22, 2025, through various international dial-in numbers. Additionally, stakeholders can access the webcast through the company's investor relations page.

Xeris Biopharma Holdings (Nasdaq: XERS) announced changes to its Board of Directors. Ricki Fairley has resigned effective immediately, while John Schmid will not seek re-election at the 2025 Annual Stockholders Meeting, which will reduce the board size to eight members.

The company has appointed James Brady as a new director to fill the immediate vacancy. Brady brings over thirty years of experience from AstraZeneca, where he held various leadership positions, most recently serving as Chief Financial Officer of MedImmune, AstraZeneca's biologics discovery and development division. He currently serves on the Board of Directors and Audit Committee of Verona Pharma plc (Nasdaq: VRNA).

Xeris Biopharma Holdings (Nasdaq: XERS) has received FDA approval for its supplemental new drug application (sNDA) of Gvoke VialDx™, the first concentrated, ready-to-dilute liquid glucagon for use as a diagnostic aid during radiologic examinations in adult patients.

The company has partnered with American Regent for commercialization in the U.S., with Xeris handling product supply while American Regent manages commercialization efforts. The product will be available in 1-count or 10-count packages of 1 mg per 0.2 mL single-dose vials, with market availability expected in Q3 2025.

This development targets the growing procedural gastroenterology market, with an estimated 20 million gastrointestinal endoscopic procedures performed annually. The product is designed to temporarily inhibit movement of the gastrointestinal tract in adult patients during radiologic examinations.

Xeris Biopharma (XERS) reported strong financial results for Q4 and full-year 2024, with record quarterly revenue of $60M (35% growth) and annual revenue of $203M (24% growth). Key product performance includes:

- Gvoke® Q4 revenue: $23.3M (+25% YoY), with 35% market share
- Recorlev® Q4 revenue: $22.6M (+131% YoY)
- Keveyis® Q4 revenue: $11.1M (-21% YoY)

The company ended Q4 with $71.6M in cash, generating $2M in cash flow and $8.3M in Adjusted EBITDA for the quarter. For 2025, Xeris projects total revenue guidance of $255M-$275M, representing over 30% growth at the mid-point.

Xeris Biopharma Holdings (Nasdaq: XERS) has announced it will release its fourth quarter and full-year 2024 financial results before U.S. markets open on March 6, 2025. The company will also provide 2025 financial guidance during this release.

Management will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day. The company currently has three commercially available products: Recorlev® for endogenous Cushing's syndrome, Gvoke® for severe hypoglycemia treatment, and Keveyis® for primary periodic paralysis. Their pipeline includes XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, along with early-stage programs utilizing their XeriSol® and XeriJect® technology platforms.

Xeris Biopharma Holdings (Nasdaq: XERS) has appointed Dr. Anh Nguyen as Chief Medical Officer (CMO), succeeding Ken Johnson, who will retire on April 1, 2025. Dr. Nguyen, who previously worked at Xeris, will oversee the company's Medical, Regulatory, Preclinical and Clinical Development, and Pharmacovigilance functions.

Dr. Nguyen brings significant experience in developing first-in-class therapies and has previously served as Vice President at Asklepios Biopharmaceutical. His past achievements include contributing to the '21st Century Cures Act' and leading Gvoke®'s NDA and MAA approvals during his previous tenure at Xeris. The transition comes as Xeris prepares for Phase 3 development of XP-8121 and continues to grow its commercial portfolio, particularly Recorlev®.

Xeris Biopharma Holdings (Nasdaq: XERS) has announced its participation in three major upcoming healthcare investor conferences in early 2025. The company will participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, featuring a fireside chat at 1:20 pm ET. Subsequently, Xeris will attend the Leerink Global Healthcare Conference in Miami on March 10, with a fireside chat scheduled for 8:40 am ET, followed by the Barclays 27th Annual Global Healthcare Conference in Miami on March 11 for 1x1 meetings only.

The growth-oriented biopharmaceutical company, focused on developing and commercializing innovative therapeutic products, will have its senior management team available for one-on-one meetings at all three events. Interested parties can access webcast information for the fireside chats through Xeris' investor relations website.

The American Diabetes Association (ADA) and Xeris Pharmaceuticals have announced a multi-year strategic partnership to promote awareness about glucagon prescriptions for diabetes patients. The collaboration focuses on emphasizing that all individuals with diabetes on blood glucose-lowering medications should have glucagon, preferably in ready-to-use form.

Key statistics highlight that up to 46% of type 1 diabetes patients and 21% of type 2 diabetes patients using insulin experience at least one severe hypoglycemia event annually. These events result in over 202,000 emergency department visits yearly, with 25% requiring hospitalization.

The partnership aims to develop educational materials and training resources for healthcare professionals and diabetes patients, alongside launching a national awareness campaign. The initiative aligns with ADA's updated Standards of Care in Diabetes—2025, addressing the critical need for proper glucagon prescription rates and emergency preparedness for those at risk of severe hypoglycemia.

Xeris Biopharma Holdings (XERS) has announced it expects to exceed its 2024 financial guidance with projected total revenue of $203 million, surpassing previous guidance of $198-$202 million. The company anticipates ending 2024 with over $71 million in cash, cash equivalents, and short-term investments, achieving positive cash flow in Q4.

Q4 2024 highlights include $60 million in total revenue, representing 35% growth, with Recorlev® net revenue increasing approximately $5 million (28%) sequentially. Gvoke® achieved approximately 35% market share, while Keveyis® maintained stable patient numbers. The company received a $3 million milestone payment from Beta Bionics for developing a XeriSol® glucagon formulation. However, Amgen terminated its exclusive worldwide license agreement following a portfolio assessment.